UK's Mission divests kidney drug to Dimerix for $292m
Mission Therapeutics out-licenses a kidney drug to Dimerix for $292m.
Mission Therapeutics
Private
UK-based drug discovery and development company focused on selective mitophagy modulation through USP30 inhibition for CNS and kidney disease.
Company Info
Sector:Biotechnology
Headquarters:Cambridge, United Kingdom
Founded:2011
Website:http://missiontherapeutics.com/
Funding Round:Series D
Total Funding:~$150M+
Funding & Investor Relations
Notable Investors
- Astellas Venture Capital
- SR One
- Pfizer Ventures
- Apposite Capital
IPO Outlook / Plans
Not currently announced
Upcoming Milestones & Key Dates
2026 H2
Clinical Readout
Phase 1 topline data for MTX325 in Parkinson's
Clinical Development Pipeline
MTX325
Target: USP30MTX652
Target: USP30Undisclosed
Target: USP30Recent News
Leadership Team
Anker Lundemose
Founder and former Chief Executive Officer
Dr. Paul Thompson
Chief Scientific Officer
Management Team
Executive Leadership